Reimbursed Care Access in Sierra Leone

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Sierra Leone’s drug-control framework is governed by the National Drugs Control Act, 2008 (and the Pharmacy & Drugs Act 2001), which creates an enforcement-led regime criminalizing unauthorized possession, importation and supply of prohibited drugs; there is no national medical/regulated access pathway or public reimbursement for psilocybin. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is internationally scheduled and Sierra Leone’s domestic law applies prohibitive criminal penalties to trafficking and unauthorised possession; there is no reimbursement or clinical access pathway in routine care. # #

Esketamine (commercialized as Spravato in some jurisdictions) is not known to be registered, reimbursed, or available as a licensed psychiatric product in Sierra Leone; there is no public record of national marketing authorization or routine reimbursement for esketamine-based products, and access would be limited to formal clinical research or special importation under regulatory exemption if ever authorized. Ketamine itself is used in Sierra Leonean hospitals (see below), but the esketamine nasal-spray product requires national regulatory approval and commercial supply chains that do not appear to exist in Sierra Leone at present. Sierra Leone’s medicines and controlled‑substances framework is set by the Pharmacy & Drugs Act 2001 and the National Drugs Control Act 2008, which would govern any authorization/import pathway. # #

Ketamine is an established medical anesthetic in Sierra Leone and is used in public and private surgical settings; it is listed on the WHO Model List of Essential Medicines for general anesthesia and appears in published reports of anesthesia practice in Sierra Leone. Ketamine’s medical availability in Sierra Leone is therefore de facto permitted for approved medical indications (primarily surgical anesthesia and emergency medicine), and its procurement and clinical use are governed through the national medicines/health system rather than as an illicit psychotropic. Reimbursement: Sierra Leone does not operate a large-scale universal pharmaceutical reimbursement program comparable to high‑income countries; essential medicines used in public hospitals (including anesthetics) are typically provided through hospital procurement and donor-supported supply chains rather than through a formal insurance reimbursement mechanism. For psychiatric use of ketamine (e.g., off‑label for depression), there is no established, reimbursed national pathway — such use would be off‑label and limited by local clinical practice and facility capability. # # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is listed by international drug-control conventions as a Schedule I substance and Sierra Leone’s domestic law applies prohibitions that prevent routine medical/reimbursed access; any use would be limited to approved clinical trials. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognized medical/reimbursement pathway in Sierra Leone for 5‑MeO‑DMT; enforcement is governed by national drug legislation. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no formal, reimbursed pathway for ibogaine in Sierra Leone; any therapeutic experimentation would require explicit regulatory approval and is not part of routine clinical practice. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although the plant preparations themselves are sometimes treated differently in some jurisdictions, DMT (the primary active constituent) is internationally scheduled and Sierra Leone’s domestic law provides no recognized legal/reimbursed pathway for ayahuasca ceremonies or clinical use. Any importation, facilitation or distribution would therefore be subject to criminal prohibition unless explicitly authorized for research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is controlled internationally and Sierra Leonean law provides no pathway for reimbursed medical use of mescaline-containing cacti or synthetic mescaline. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. '2C‑X' class phenethylamines (and related synthetic psychoactives) are captured by Sierra Leone’s prohibitions on designer/novel psychoactive substances and there is no legal/reimbursed pathway for therapeutic use. # #